Loading…
HeartSciences Inc. is projected to rise to $2.38 by 2027, a +11% move from its current price of $2.14. HSCS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $2.04 | $2.14 | $2.24 | +0.04% |
| Aug 6 | $2.00 | $2.14 | $2.29 | +0.08% |
| Aug 7 | $1.97 | $2.14 | $2.33 | +0.12% |
| Aug 8 | $1.95 | $2.14 | $2.36 | +0.16% |
| Aug 9 | $1.93 | $2.14 | $2.38 | +0.21% |
| Aug 10 | $1.91 | $2.15 | $2.41 | +0.25% |
| Aug 11 | $1.89 | $2.15 | $2.43 | +0.29% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.89 | $2.15 | $2.43 | +0.29% |
| Week 2 | $1.80 | $2.15 | $2.57 | +0.58% |
| Week 3 | $1.74 | $2.16 | $2.68 | +0.87% |
| Week 4 | $1.69 | $2.16 | $2.78 | +1.16% |
| Week 5 | $1.64 | $2.17 | $2.87 | +1.45% |
| Week 6 | $1.60 | $2.18 | $2.96 | +1.74% |
| Week 7 | $1.57 | $2.18 | $3.04 | +2.03% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic ECG management platform.
The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.
These facts place HeartSciences in the Healthcare category and describe its focus on AI-enabled ECG solutions and related platforms while noting its corporate evolution and origins.
HeartSciences Inc. (HSCS) trades in the Healthcare sector. The stock is currently priced at $2.08 with a market capitalization of $8.11M and a rank of 4867.
Near-term indicators show a bearish tilt while longer-term forecasts point to significant upside. The 30-day forecast provides a wide price path that expands meaningfully by the late 2020s and beyond, with average prices rising from $2.08 in 2026 to $9.65 by 2050 and max values reaching $22.20.
The forecast emphasizes steady to accelerating upside in coming years, with year-by-year averages and ROIs suggesting a bullish multi-year trajectory despite a conservative near-term tone. This landscape highlights potential upside for investors who can tolerate near-term volatility.
A major floor 48.9% below — a decisive break under it would weaken the trend.
The nearest floor, 17.3% below — buyers have tended to step in here.
The nearest ceiling, 39.7% above — a clean break opens room to run.
A major ceiling 65.1% above — clearing it would confirm fresh momentum.
Key HSCS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HSCS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.24 | Sell | $2.22 | Sell |
| MA 10 | $2.36 | Sell | $2.33 | Sell |
| MA 20 | $2.53 | Sell | $2.41 | Sell |
| MA 50 | $2.29 | Sell | $2.36 | Sell |
| MA 100 | $2.23 | Sell | $2.39 | Sell |
| MA 200 | $2.59 | Sell | $2.71 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.44 | Neutral |
| Stoch RSI (14) | 20.06 | Neutral |
| CCI (20) | -132.38 | Sell |
| Williams %R (14) | -84.85 | Info |
| MACD (12,26,9) | -0.08 | Sell |
| ROC (12) | -14.84 | Sell |
| Bollinger %B (20,2) | 0.09 | Neutral |
| Stochastic %K (14) | 15.15 | Buy |
| TRIX (15) | 0.20 | Buy |
| Awesome (5,34) | -0.22 | Sell |
| Ultimate (7,14,28) | 34.46 | Neutral |
| Momentum (10) | -0.51 | Sell |
| Aroon Osc (25) | -96.00 | Sell |
| Hull MA (9) | 2.08 | Buy |
| ADX (14) | 13.88 | Neutral |
| ATR (14) | 0.12 | Info |
Technical perspective for the next 30 days shows bearish sentiment overall. RSI14 is 40, indicating modest momentum toward the downside.
The stock’s moving averages sit at SMA50 = $2.28 and SMA200 = $2.60, with the price currently near the lower end of the trajectory. The 30-day range spans from $1.52 to $2.85, providing near-term support around $1.77 and resistance near $2.99.
Overall, the short-term picture suggests caution, as momentum and price action are less favorable in the immediate period, even as longer-run forecasts imply potential upside.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.67 | $2.14 | $2.89 | 0% | Neutral | |
| $1.77 | $2.38 | $3.44 | +11% | Neutral | |
| $2.00 | $2.83 | $4.34 | +32% | Bullish | |
| $2.34 | $3.47 | $5.57 | +62% | Bullish | |
| $2.46 | $3.79 | $6.31 | +77% | Bullish | |
| $2.00 | $3.21 | $5.52 | +50% | Bullish | |
| $2.00 | $3.32 | $5.88 | +55% | Bullish | |
| $2.07 | $3.55 | $6.44 | +66% | Bullish | |
| $1.74 | $3.09 | $5.74 | +44% | Bullish | |
| $2.28 | $4.18 | $7.94 | +95% | Bullish | |
| $2.09 | $4.44 | $9.21 | +107% | Bullish | |
| $4.87 | $10.82 | $24.89 | +406% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.67 | $2.14 | $2.71 | +0.00% |
| September 2026 | $1.92 | $2.32 | $2.92 | +8.55% |
| October 2026 | $1.82 | $2.22 | $2.84 | -4.36% |
| November 2026 | $1.71 | $2.12 | $2.75 | -4.71% |
| December 2026 | $1.76 | $2.20 | $2.89 | +3.85% |
Click any year to see its month-by-month HSCS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
HeartSciences Inc.'s 2026 outlook centres on $2.14, within a $1.67 to $2.89 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, HSCS could reach as high as $3.44, with a base case around $2.38 and support toward $1.77 — roughly +11% from $2.14. A consolidation phase looks the most probable path here.
Expect HSCS to range from $2.00 to $4.34 through 2028. The $2.83 average target implies a +32% move from current prices. That is up +19% on the projected 2027 average. Momentum favours further upside here.
The HSCS price prediction for 2029 points to an average of $3.47 (low $2.34, high $5.57) — a potential gain of +62% on today's $2.14. Buyers look set to stay in control over this stretch.
In 2030, HSCS is projected to trade between $2.46 and $6.31, averaging $3.79 — a potential gain of +77% from today's $2.14. That is up +9% on the projected 2029 average. Momentum favours further upside here.
HeartSciences Inc.'s 2031 outlook centres on $3.21, within a $2.00 to $5.52 range. That is -15% versus the projected 2030 average. That marks a +50% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, HSCS could reach as high as $5.88, with a base case around $3.32 and support toward $2.00 — roughly +55% from $2.14. Momentum favours further upside here.
Expect HSCS to range from $2.07 to $6.44 through 2033. The $3.55 average target implies a +66% move from current prices. That is up +7% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The HSCS price prediction for 2034 points to an average of $3.09 (low $1.74, high $5.74) — a potential gain of +44% on today's $2.14. Momentum favours further upside here.
In 2035, HSCS is projected to trade between $2.28 and $7.94, averaging $4.18 — a potential gain of +95% from today's $2.14. That is up +35% on the projected 2034 average. Buyers look set to stay in control over this stretch.
HeartSciences Inc.'s 2040 outlook centres on $4.44, within a $2.09 to $9.21 range. That is up +6% on the projected 2035 average. That marks a +107% change versus current levels. Momentum favours further upside here.
By 2050, HSCS could reach as high as $24.89, with a base case around $10.82 and support toward $4.87 — roughly +406% from $2.14. Buyers look set to stay in control over this stretch.
Investing $1,000 in HSCS today (≈ 467.28972 HSCS) could be worth
$5,056.34
+$4,056.34 (+406%) by 2050 · US Dollar
Based on the average projected HSCS price of $10.82 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HSCSwould be worth at today's price.
$1,000 invested in HSCS on Jul 31, 2025 (≈ 320.512832 HSCS) would be worth
$685.9
-$314.1 (-31.4%) today · 0.69× · US Dollar
Based on a HSCS entry price of $3.12 vs. today's $2.14.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.39 | $895.4 | -10.5% |
| 1 month ago | $2.94 | $727.89 | -27.2% |
| 3 months ago | $1.99 | $1,075.38 | +7.5% |
| 6 months ago | $3.2 | $668.75 | -33.1% |
| 1 year ago | $3.12 | $685.9 | -31.4% |
| All time (4.1y) ago | $242 | $8.84 | -99.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HSCS forecast.
Our base-case forecast reaches $4.30 around 2040.
Implied market cap at $4.30: $16.77M
The multi-year forecast shows a bullish trajectory beginning in the later part of the decade and continuing into the 2030s and beyond. In 2026 the average price is projected to be $2.08 with an ROI of 0% and a neutral sentiment, rising to an average of $3.53 by 2030 with a 69.8% ROI.
Key milestones include 2027 at $2.23 (7.1% ROI), 2028 at $2.65 (27.5% ROI), and 2029 at $3.27 (57.3% ROI). By 2031 the forecast shows $3.01 avg with 44.8% ROI, rising to $3.12 in 2032 (50.1%), and $3.26 in 2033 (57%). The 2035 projection is $3.78 avg with an 81.7% ROI, and 2040 projects $4.05 avg with 94.5% ROI.
The long-run pinnacle appears in 2050 with an average of $9.65 and a 364% ROI, with a max forecast of $22.20.
Sentiment shifts from neutral in 2026 to bullish from 2027 onward, reflecting a positive longer-term outlook despite near-term volatility and elevated uncertainty.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $3.53 with a min of $2.28 and a max of $5.90, and an ROI of 69.8% with bullish sentiment.
The multi-year forecast indicates a bullish trajectory from 2027 onward, with average prices rising to $9.65 by 2050 and a maximum forecast of $22.20, yielding an ROI of 364% in 2050.
Yes. The 2050 max forecast is $22.20, which exceeds $20.
The current price is $2.08 and the market cap is $8.11M.
The 30-day picture shows bearish sentiment with RSI 14 at 40. The SMA10? No—the 50-day SMA is $2.28 and the 200-day SMA is $2.60. The 30-day range is $1.52 to $2.85, with support at $1.77 and resistance at $2.99.
HeartSciences Inc. Community Discussion
0Share your HeartSciences Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.